Trump's 2nd Administration Launched...What are domestic companies' strategies for changing the global pharmaceutical bio landscape?
Jan 20, 2025
|
In the 27th Policy Report (KPBMA Brief) published by the Korea Pharmaceutical Bio Association on the 19th under the theme of 「Global Success Strategies of Korean Pharmaceutical Bio Companies」, Lee Hyo-young, an associate professor of the National Diplomatic Institute, made a comprehensive diagnosis on the impact of external variables such as the 2nd Trump administration on the global pharmaceutical bio industry landscape through suggestions titled 「Changes in the global pharmaceutical bio landscape and the response of Korean pharmaceutical bio companies」.
The United States has been making efforts to reduce its dependence on foreign drugs, including proposing the 「BioSecure Act」. In particular, with the launch of the second Trump administration, the policy to strengthen checks on China is expected to be further strengthened in the future, which could serve as an opportunity for Korean pharmaceutical bio companies that are competing with China. According to the explanation, Europe is continuing to ease related regulations and promote investment by announcing the 「European Pharmaceutical Industry Strategy" in 2020, forming the 「Core Drug Union" along with the announcement of a mid- to long-term strategy to stabilize the supply of drugs in 2023. Japan also establishes 'Bio Strategy 2019/2020', 'Vaccine Development, Production System Enhancement Strategy', 'Bioeconomic Strategy', and 'Bioeconomic Strategy Action Plan' to realize a state-of-the-art bioeconomic society by 2030.
Professor Lee added, "We need to re-examine our supply chain of pharmaceutical biopharmaceuticals and solidify the international cooperation system in related fields in preparation for further intensifying competition in the global pharmaceutical biopharmaceuticals sector in the future.", he explained. In addition, the government needs support to actively develop high value-added products through R&D and technological innovation in biopharmaceutical fields in the mid to long term""Active support for industrial development and active technological innovation efforts by companies should be made to maintain an edge and strengthen their influence in the field of biopharmaceuticals with export competitiveness "
On the other hand, this policy report included suggestions, ▲ Korean pharmaceutical bio industry, the way to global expansion (Lee Hyun-woo, global head of the Korea Pharmaceutical Bio Association) ▲ Global (China) success strategy of Korean pharmaceutical bio companies (Lee Sang-jae, CEO of Scherder Corporation) ▲ Direct sales of U.S. drugs: Key elements and preparation strategies for success (CEO Ahn Se-jin of Arcadia) ▲ Strategies for Korean pharmaceutical companies to enter the overseas drug procurement market (Son Kyung-bok, professor of the College of Pharmacy at Hanyang University) ▲ Considerations when attracting domestic and foreign investments.
Cases of domestic companies' actual global expansion strategy were also dealt with from various angles. Oh Se-woong, Vice President of Yuhan Corporation, 'Yuhan Corporation 'Leklaja'…From Technology Export to FDA Approval'The implications of FDA approval of lung cancer drug 'Leklaza' through contributions, and GC Green Cross Development Director Lee Jae-woo introduced the entry into the U.S. market for blood drug 'Ali Glo' through 'Ali Glo FDA approval: suggestions for the next BLA task'. In addition, ▲ Global CDMO Market Attack Plan: Establishment of Production Factory (Lee Sang-ho, Deputy of Lotte Biologics Global Public Relations Team) ▲ Reason why Usinrabortachi entered Slovenia (Cha Tae-yong, Managing Director of Usinrabortachi) was included.
Along with ▲ Advanced biotechnology trends and emerging security issues (Kim Heung-yeol, head of the Biotechnology Policy Research Center at the Korea Biotechnology Research Institute) ▲ Trends and suggestions for high-tech regenerative medical treatments and treatment technologies at home and abroad (Cho In-ho, head of the pan-ministerial regenerative medical technology development project) ▲ Diffusion of protectionism and ESG response tasks (Park Se-yeon, senior researcher at Hanwha Investment & Securities Research Center) ▲ Initiation and utilization value of double drug prices (Kang Hee-sung, member of the Pharmaceutical and Biological Association's Pharmaceutical Price System and Distribution Committee It also contains contributions from his back.
Han Sang-hee, Vice President of AI Research Institute, explained in a contribution under the theme of 「Trend of innovative technology in manufacturing drugs using advanced technologies such as AI」"In order to introduce advanced manufacturing innovation technologies in the pharmaceutical industry, government-level data standardization and integration support, strengthening the verification system of AI technology, expanding financial support, establishing regulatory science-based policies, and nurturing professional talent are necessary."
This article was translated by Naver AI translator.
